Although the number of therapies targeted to driver oncogenes of gastric cancer is limited, a humanized monoclonal antibody against HER2 (trastuzumab) was approved by the United States Food and Drug Administration (USFDA) for the treatment of patients with metastatic gastric cancer that overexpress HER21,2. Here, ERBB2 is linked to gastric cancer.